Achyut Healthcare Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Achyut Healthcare Ltd is ₹ 5.37 as of 06 May 15:30 . The P/E Ratio of Achyut Healthcare Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Achyut Healthcare Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Achyut Healthcare Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Achyut Healthcare Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Achyut Healthcare Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Achyut Healthcare Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Achyut Healthcare Ltd

Achyut Healthcare Limited was incorporated as Achyut Securities Private Limited' on January 11, 1996 as a Private Limited Company under the Companies Act, 1956 with the Registrar of Companies, Gujarat, Dadra and Nagar Haveli.
The Company name was changed to Achyut Healthcare Private Limited', and a fresh Certificate of Incorporation dated November 26, 2002.
Subsequently, the Company got converted from a Private Limited to Public Limited and the name of the Company changed to Achyut Healthcare Limited', and a fresh Certificate of Incorporation dated November 30, 2021 was issued to the Company by Registrar of Companies, Gujarat at Ahmedabad. The Company is engaged in trading of Cenzure, Arpimune, Azathioprine IP, Everolimus, Mycophenolate Mofetil USP, Mycophenolate Sodium USP, Sirolimus, Tacrolimus USP, Infrared thermometer, Ascorbic Acid Coated Vitamin C, Calcium carbonate oyster, Cellulose acetate Phthalate, Chlorthalidone IP, Croscarmellose Sodium IP/USP, DIBasic Calcium Phosphate IP, DIEthyl Phthalate, Diltiazem Hydrochloride IP, Easy Coat Fc Titanium Dioxide, Escitalopram IP, Escitalopram Oxalate, Favipiravir among many other products.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Achyut Healthcare Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Achyut Healthcare Ltd or Sanofi India Ltd?

Market cap of Achyut Healthcare Ltd is 126 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Achyut Healthcare Ltd and Sanofi India Ltd?

The stock performance of Achyut Healthcare Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Achyut Healthcare Ltd and Sanofi India Ltd?

As of May 6, 2026, the Achyut Healthcare Ltd stock price is INR ₹5.37. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Achyut Healthcare Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Achyut Healthcare Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.